Brian Druker, M.D., president of Knight Cancer Group, oversees strategy, sets priorities and guides the overall direction of the Knight Cancer Institute. In this role, he leads the board of directors as president and works closely with OHSU executive leaders. An internationally renowned physician-scientist, Druker developed Gleevec, which transformed chronic myeloid leukemia from a fatal disease into a manageable condition and launched the era of precision medicine.

Since joining OHSU in 1993, Druker has helped build the institute into a globally recognized leader in cancer research, prevention, early detection and patient care. In 2025, following a historic $2 billion commitment from Phil and Penny Knight, Druker embarked on an ambitious new chapter for the Knight Cancer Institute. This investment is intended to create a fully integrated cancer care model that will expand and accelerate diagnostics, ensure access to innovative clinical trials informed by Knight research and simplify the experience for patients and families.

Druker earned his medical degree from University of California, San Diego. He completed his internship and residency at Washington University School of Medicine in St. Louis, followed by fellowship training in medical oncology at Dana-Farber Cancer Institute and Harvard Medical School. He is a member of the National Academy of Medicine, the National Academy of Sciences and has received many of medicine’s highest honors, including the Lasker-DeBakey Award, Japan Prize, Tang Prize, Warren Alpert Prize and Sjöberg Prize.